Literature DB >> 3349449

Elevated DNA polymerase beta activity in a cis-diamminedichloroplatinum(II) resistant P388 murine leukemia cell line.

A J Kraker1, C W Moore.   

Abstract

The activity of DNA polymerase beta, which is an enzyme involved in repair of DNA damage, was assessed in P388 murine leukemia cell lines sensitive and resistant to cis-diamminedichloroplatinum(II) (cis-Pt). The resistant line was selected with cis-Pt and showed cross-resistance to a number of alkylating agents, but not to an anthracycline. The DNA polymerase beta activity was found to be elevated 5-fold in the resistant line based upon activity per mg cell protein and elevated 4-fold based upon activity per 10(7) cells. The characterization of elevated activity of an enzyme active in DNA repair in a cell line resistant to DNA damaging agents describes a possible mechanism of resistance in addition to those previously found.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3349449     DOI： 10.1016/0304-3835(88)90022-5

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  8 in total

1.  Structural basis for the inefficient nucleotide incorporation opposite cisplatin-DNA lesion by human DNA polymerase β.

Authors:  Myong-Chul Koag; Lara Lai; Seongmin Lee
Journal:  J Biol Chem       Date:  2014-09-18       Impact factor: 5.157

2.  Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.

Authors:  William R Waud; Karen S Gilbert; John A Secrist
Journal:  Cancer Chemother Pharmacol       Date:  2010-11-11       Impact factor: 3.333

3.  Strategic down-regulation of DNA polymerase beta by antisense RNA sensitizes mammalian cells to specific DNA damaging agents.

Authors:  J K Horton; D K Srivastava; B Z Zmudzka; S H Wilson
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

4.  Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.

Authors:  W R Waud; S D Harrison; K S Gilbert; W R Laster; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.

Authors:  W R Waud; J Plowman; S D Harrison; D J Dykes; W K Anderson; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Characterization of DNA polymerase beta mutants with amino acid substitutions located in the C-terminal portion of the enzyme.

Authors:  J B Sweasy; M S Yoon
Journal:  Mol Gen Genet       Date:  1995-07-28

7.  Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling.

Authors:  A K M Azad; Alfons Lawen; Jonathan M Keith
Journal:  BMC Syst Biol       Date:  2015-01-20

Review 8.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.